Codebase Ventures Inc.: Codebase Receives Positive Technical Study Results for HCQ Transdermal Patch Technology
Viability to Address Underserved Lupus, Rheumatoid Arthritis and Malaria market, forecast to be worth $6 Billion USD by 2027*, Company to investigate Spin Out of Asset
VANCOUVER, BC / ACCESSWIRE / April 1, 2021 / Codebase Ventures Inc. ("Codebase" or the "Company") (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is pleased to provide an update on the continued development of the Company's proposed transdermal delivery technology for hydroxychloroquine (HCQ), as first announced in April 2020.
The Company engaged TRPL (Transdermal Research Pharm Laboratories) of Long Island City of New York, to conduct a feasibility study which indicates that HCQ has all the required parameters to be a transdermal candidate.